Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lebwohl

Showing results (161-170 of 173) with videos related to

Pageof 18
Sort By:
The British Journal of Dermatology|April 8, 2021
The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-upM Lebwohl, A Deodhar, C E M Griffiths, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 3, 2017
Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trialsL Guenther, R B Warren, J C Cather, et al.
The British Journal of Dermatology|October 14, 2014
Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-upR G Langley, M Lebwohl, G G Krueger, et al.
The British Journal of Dermatology|January 11, 2013
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-upK A Papp, C E M Griffiths, K Gordon, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 7, 2018
Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foamA Jalili, M Lebwohl, L Stein Gold, et al.
Journal of the American Academy of Dermatology|February 25, 2000
Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasisA Gottlieb, J G Krueger, R Bright, et al.
The British Journal of Dermatology|March 17, 2017
Reaching complete or near-complete resolution of psoriasis: benefit and risk considerationsA Blauvelt, C E M Griffiths, M Lebwohl, et al.
Archives of Dermatology|June 2, 1998
Consensus workshop on the toxic effects of long-term PUVA therapyW L Morison, R D Baughman, R M Day, et al.
Journal of the American Academy of Dermatology|February 1, 1996
Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994M A Menter, J A See, W J Amend, et al.
Journal of the American Academy of Dermatology|May 20, 1998
Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasisM Lebwohl, E Ast, J P Callen, et al.
Pageof 18

Showing results (161-170 of 173) with videos related to

Sort By:
Pageof 18
The British Journal of Dermatology|April 8, 2021
The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-upM Lebwohl, A Deodhar, C E M Griffiths, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 3, 2017
Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trialsL Guenther, R B Warren, J C Cather, et al.
The British Journal of Dermatology|October 14, 2014
Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-upR G Langley, M Lebwohl, G G Krueger, et al.
The British Journal of Dermatology|January 11, 2013
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-upK A Papp, C E M Griffiths, K Gordon, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 7, 2018
Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foamA Jalili, M Lebwohl, L Stein Gold, et al.
Journal of the American Academy of Dermatology|February 25, 2000
Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasisA Gottlieb, J G Krueger, R Bright, et al.
The British Journal of Dermatology|March 17, 2017
Reaching complete or near-complete resolution of psoriasis: benefit and risk considerationsA Blauvelt, C E M Griffiths, M Lebwohl, et al.
Archives of Dermatology|June 2, 1998
Consensus workshop on the toxic effects of long-term PUVA therapyW L Morison, R D Baughman, R M Day, et al.
Journal of the American Academy of Dermatology|February 1, 1996
Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994M A Menter, J A See, W J Amend, et al.
Journal of the American Academy of Dermatology|May 20, 1998
Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasisM Lebwohl, E Ast, J P Callen, et al.
Pageof 18